11 results about "Hematochezia" patented technology

The invention provides a method for evaluating the intestinal toxicity of nano polypropylene plastic, which comprises the following steps of: 1, exposing macrophages in a culture medium containing polypropylene nano particles with different concentrations and / or different particle sizes for culturing, and detecting any one or more of cell survival rate, glucose consumption level, lactic acid production level and glycolysis level; the method 2 comprises the following steps: exposing an enteritis model mouse in the polypropylene nano-plastic, recording the fecal state, hematochezia degree and weight during administration, and / or calculating a disease activity index, and / or detecting the pathological state of the intestinal tract of the mouse. The invention focuses on analyzing the influence of the polypropylene nano-plastic on glycolysis of macrophages, reveals the potential effect of the polypropylene nano-plastic on enteritis progression, and provides theoretical basis and technical support for prevention and treatment of nano-plastic related diseases.

The application relates to the technical field of traditional Chinese medicine preparation, and particularly discloses a compound traditional Chinese medicine preparation for targeting egg duck and goose egg cytoplasmic disease, which comprises the following components: white head, Coptis chinensis, Huangqi, Phellodendron amurense, wine Danpi, bran-fried peach kernel, Chinese perilla, pomegranate peel, liquorice, honeysuckle, Andrographis, figwort, emblic, ginger, fried atractylodes, fried safflower, Xianhecao, spiny amaranth, and Poria cocos. Through the combination of monarch, minister, assistant and messenger, the core effects of heat-clearing and detoxifying, blood-cooling and dysentery-stopping, and dampness-drying and insect-killing of the medicines are synergistically exerted, the pathogenesis characteristics of the egg cytoplasmic disease are accurately targeted, blood stasis and blood circulation are promoted to eliminate the swelling of the lesion, and the intestinal mucosa damage is repaired to stop bleeding, the symptoms of hematochezia, diarrhea and oviduct inflammation of the egg duck and goose caused by the egg cytoplasmic disease are effectively relieved, the problems of the decreased antibiotic effect, drug residue, bacterial flora disorder and food safety risk are effectively solved, and the compound traditional Chinese medicine preparation has the remarkable progress of drug resistance, safety, no residue, intestinal protection and green environmental protection.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine intestinal administration preparation for treating UC and a preparation method. The traditional Chinese medicine intestinal administration preparation for treating UC comprises the following raw material medicines in parts by weight: 20-50 parts of rhizoma coptidis, 20-50 parts of cortex phellodendri, 20-50 parts of radix sanguisorbae, 20-50 parts of radix paeoniae alba, 20-50 parts of rhizoma bletillae, 10-40 parts of radix sophorae flavescentis and 10-40 parts of liquorice root. The composition is prepared by combining various medicines, has the effects of eliminating dampness and heat, cooling blood, stopping bleeding, astringing sores and promoting tissue regeneration, and the seven medicines are used together, so that the treatment effect is improved, a synergistic effect is achieved, and the composition is good in effect and free of toxic and side effects when being used for clinical treatment of UC for a long time; the preparation has strong heat-clearing and bleeding-stopping effects, can quickly relieve symptoms such as stomachache, tenesmus and hematochezia caused by UC, and effectively promotes intestinal mucosa healing.

The application discloses a folate-chicoric acid liposome for treating ulcerative colitis and a preparation and application thereof, and relates to the technical field of veterinary drugs. The folate-chicoric acid liposome is composed of egg yolk lecithin, cholesterol, chicoric acid and folate (mass ratio of 10-14:2-5:1-2:1-2), has targeting property, has the effect of targeting macrophages, inhibits the polarization of macrophages to M1 type, can improve the clinical symptoms (weight loss, hematochezia and the like) of ulcerative colitis mice, increase the colon length, reduce the DAI score, the CMDI score and the colon index, relieve the pathological damage of the colon and relieve intestinal inflammation. The liposome has the effect of treating ulcerative colitis mice, and can provide an efficient drug for treating ulcerative colitis in the livestock breeding industry. Meanwhile, the liposome has the advantages of simple preparation method, good treatment effect, high specificity, safety and non-toxicity.

The application discloses a traditional Chinese medicine composition for treating ulcerative colitis and a preparation method and application thereof, and relates to a traditional Chinese medicine composition for treating ulcerative colitis, which is composed of the following components in proportion by weight: radix astragali, rhizoma coptidis, radix scrophulariae, bletilla striata, indigo naturalis, rhizoma corydalis and radix glycyrrhizae. The application has the following remarkable advantages: remarkable synergistic effect, the effect of the traditional Chinese medicine composition of the application on improving the weight loss, hematochezia, DAI score and reducing intestinal inflammation of ulcerative colitis mice is remarkably better than that of any single medicine in the important composition, which proves that there is a remarkable synergistic effect among the components; the mucosal barrier protection is better than that of infliximab; the comprehensive curative effect is equivalent, and the compliance is better; and the drug economy has the advantages that the medicinal materials selected by the application are common traditional Chinese medicines, are widely sourced and are low in price, thereby greatly reducing the treatment cost of patients and being suitable for long-term maintenance treatment.

The invention discloses modified radix puerariae, radix scutellariae and rhizoma coptidis decoction with an intestinal flora regulating function for treating ulcerative colitis, and the modified radix puerariae, radix scutellariae and rhizoma coptidis decoction is mainly prepared from the following raw materials in parts by mass: 20-28 parts of radix puerariae, 6-12 parts of radix scutellariae, 6-12 parts of rhizoma coptidis, 3-9 parts of honey-fried licorice root, 3-9 parts of radix paeoniae alba, 6-12 parts of fructus jujubae, 9-15 parts of vinegar schisandra chinensis and 1-6 parts of fructus evodiae. According to the modified radix puerariae qinlian decoction (MGQD) disclosed by the invention, cold and warm medicines are used together, so that the effects of clearing heat and tonifying healthy qi are achieved, the imbalance of intestinal flora of ulcerative colitis can be effectively reversed, the diversity of the intestinal flora can be enhanced, the relative abundance of beneficial bacteria such as Muriacaceae, Lacnospiraceae NK4A136group and Lactobacillus can be increased, the level of metabolite bile acid of the intestinal flora can be regulated, and the curative effect of the ulcerative colitis can be improved. According to the traditional Chinese medicine composition, the protein expression of TGR5 and FXR in a colon tissue is up-regulated, the injury caused by colitis is relieved, inflammatory cell infiltration of the colon tissue is reduced, the number of goblet cells is increased, the symptoms such as stomachache, diarrhea and hematochezia can be effectively improved clinically, the illness state is controlled to be stable, the recurrence period is prolonged, and recurrence is reduced.

The invention discloses an intestinal fungus Yarrowia lipolytica (Yarrowia lipolytica) PT3309 derived from healthy people and application of the intestinal fungus Yarrowia lipolytica PT3309, and belongs to the field of functional microorganisms. The strain preservation number of the yarrowia lipolytica PT3309 is GDMCC (Grains Database Microorganism Center) 65342. The yarrowia lipolytica PT3309 can tolerate the gastrointestinal environment of a human body, and can be efficiently adhered to an intestinal epithelial cell Caco2. The yarrowia lipolytica PT3309 and biomass energy thereof can relieve weight loss, hematochezia and diarrhea of inflammatory bowel disease model mice, improve colon pathological changes, reduce expression of inflammatory factors such as IL-1beta, IL-6 and TNF-alpha, and restore colon epithelial barriers. The Yarrowia lipolytica PT3309 provided by the invention can be used for preparing functional microbial agents, foods and medicines for relieving inflammatory bowel diseases, and has a wide application prospect.

The invention discloses application of a gingko armillaria mellea oral solution in preparation of a medicine for preventing and treating inflammatory bowel diseases. Through a prevention and treatment test of the ginkgo armillaria mellea oral solution on mouse ulcerative colitis, a C57BL / 6 mouse DSS induction method is adopted to construct a model, and the effect of 390mg / kg and 780mg / kg of the ginkgo armillaria mellea oral solution on resisting mouse inflammatory bowel diseases is evaluated. The result shows that the gingko armillaria mellea oral solution can obviously improve the mouse hematochezia condition; the colon length is increased, the colon weight / length ratio is reduced, and colonic mucosa hyperemia is reduced; the weight is increased. Therefore, the gingko armillaria mellea oral solution has the characteristics of high efficiency and low toxicity for preventing and / or treating inflammatory bowel diseases.

The invention discloses a folic acid-echinacea source alkyl amide liposome for treating ulcerative colitis as well as preparation and application of the folic acid-echinacea source alkyl amide liposome. The folic acid-echinacea source alkylamide liposome is prepared from egg yolk lecithin, cholesterol, echinacea source alkylamide and phospholipid-polyethylene glycol-folic acid (the mass ratio is (4-8): (2-5): (1-2): (1-2)), has targeting property and macrophage targeting effect, and can improve clinical symptoms (weight loss, bloody stool and the like) of mice with ulcerative colitis, increase the colon length and improve the ulcerative colitis activity. The DAI score and the indexes of all organs and colon are reduced, the colon pathological injury is relieved, and the intestinal inflammation is relieved. The liposome shows a good effect of treating mice with ulcerative colitis, a novel nano-liposome drug is provided for treatment of ulcerative colitis, and a certain foundation is laid for research and development of new drugs for treating ulcerative colitis. Meanwhile, the preparation method has the advantages of being simple, good in treatment effect, high in specificity, safe and non-toxic.

The invention belongs to the technical field of biological medicines, and relates to application of exogenous mitochondria in preparation of a medicine for treating colitis, and the exogenous mitochondria is derived from mammary epithelial cells. The exogenous mitochondria derived from mammary epithelial cells is used for treating young individual colitis for the first time, and the symptoms including inhibition of weight loss, improvement of diarrhea and hemafecia, repair of colonic mucosal lesion (such as crypt structure damage and inflammatory cell infiltration) and / or reduction of disease activity index (DAI score) can be remarkably relieved; the problems that in the prior art, mitochondria sources are limited, oral stability is poor, and the curative effect verification of a young model is insufficient are solved, and a new strategy is provided for colitis treatment.

The invention discloses a macrolide compound and application thereof in preparation of a product for treating ulcerative colitis, and relates to the technical field of biological medicines. In the research process of a secondary metabolite of a strain Penicillium brefeldianum GXIMD 02511 sourced from rhizosphere bottom mud in a mangrove forest protection area at the river estuary of Guangxi province, a macrolide compound brefeldin N is obtained through separation, and the macrolide compound brefeldin N has a remarkable treatment effect on DSS-induced ulcerative colitis mice and can be used for preparing a medicine for treating the ulcerative colitis. Clinical symptoms such as weight loss, hemafecia and diarrhea in the acute stage are remarkably relieved, colon shortening is relieved, pathological injuries are improved, and the effect is better than that of 5-ASA. Therefore, the compound is an ideal candidate compound developed into a novel medicine for treating ulcerative colitis.